Truist raised the firm’s price target on Teva (TEVA) to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: